1. One more reason to fund the Global Fund
Oliver Sabot, Shanelle Hall 
The Lancet 
Volume 379, Issue 9813, Pages e25-e26 (January 2012)
DOI: /S (11)61756-X
Copyright © 2012 Elsevier Ltd Terms and Conditions

2. Figure
Price and volume of artemether-lumefantrine in the public sector before and after the Global Fund and WHO actively facilitate the switch to ACTs
ACTs=artemisinin-based combination therapies. In 2004, the Global Fund, working with WHO, provided many of its recipient countries with the impetus and financing necessary to rapidly change from suboptimal therapies (eg, chloroquine) to ACTs.
The Lancet  , e25-e26DOI: ( /S (11)61756-X)
Copyright © 2012 Elsevier Ltd Terms and Conditions